Page last updated: 2024-12-05

sec-butylbenzene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sec-butylbenzene : An alkylbenzene that is benzene substituted by a butan-2-yl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8680
CHEMBL ID27516
CHEBI ID35097
MeSH IDM0176067

Synonyms (57)

Synonym
1-methyl-propyl-benzene
2-phenylbutane
nsc-8466
(1-methylpropyl)benzene
nsc8466
wln: 2y1 & r
135-98-8
benzene, sec-butyl-
benzene, (1-methylpropyl)-
sec-butylbenzene
secondary butylbenzene
inchi=1/c10h14/c1-3-9(2)10-7-5-4-6-8-10/h4-9h,3h2,1-2h
hsdb 7212
einecs 205-227-0
nsc 8466
brn 1903902
ai3-00121
sec-butylbenzene, >=99%
s-butylbenzene
CHEBI:35097 ,
B0714
CHEMBL27516
sec-butyl-benzene
butan-2-ylbenzene
FT-0656443
S0663
AKOS000120879
einecs 270-126-0
ec 270-126-0
unii-b70i0rsx3j
2-05-00-00319 (beilstein handbook reference)
b70i0rsx3j ,
butan-2-ylbenzol
sec-butylbenzene [mi]
(+/-)-sec-butylbenzene
butylbenzene, sec-
sec-butylbenzene [hsdb]
AKOS022179304
secbutylbenzene
sec-butyl benzene
2-phenyl butane
.alpha.-methylpropylbenzene
tox21_303828
NCGC00356966-01
dtxcid902333
dtxsid2022333 ,
cas-135-98-8
36383-15-0
1-sec-butylbenzene
mfcd00009329
sec-butylbenzene, analytical standard
J-006792
F0001-0456
(butan-2-yl)benzene
Q27116415
EN300-20464
N11903
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkylbenzeneA monocyclic arene that is benzene substituted with one or more alkyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.44830.001530.607315,848.9004AID1224841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID167125Eye irritation potential accessed using Draize in vivo rabbit eye irritation test2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
AID24227Partition coefficient (logP)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.39 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index59.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]